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ABSTRACT
Bacteriophage RNA polymerases are widely used to
synthesize defined RNAs on a large scale In vitro.
Unfortunately, the RNA product contains a small
proportion of contaminating RNAs, including
complementary species, which can lead to errors of
interpretation. We cloned the gene encoding Ad2 VA
RNA, into a vector containing a T7 RNA polymerase
promoter in order to generate large quantities of VA
RNA for the study of its interaction with the dsRNA-
dependent protein kinase DAI. Exact copies of VA
RNA! were synthesized efficiently, but were
contaminated with small amounts of dsRNA which
activated DAI and confounded interpretation of kinase
assays. We therefore developed a method to remove
the dsRNA contaminants, allowing VA RNA| and
mutants to be tested for their ability to activate or inhibit
DAI. This method appears to be generally applicable.
INTRODUCTION
VA RNA was discovered as an abundant RNA present in KB
cells infected with adenovirus type 2 (Ad2; ref. 1). Subsequently
it was realized that there are two such RNAs, VA RNA] and
VA RNAn, both about 160 nucleotides in length (2). The RNAs
accumulate to high levels (about 108 and 107 copies per cell,
respectively) in the cytoplasm of infected cells (3), and their
sequences suggest that they can adopt stable secondary structures
(4,5). They are encoded by closely spaced genes located at
approximately map unit 30 on the adenoviral genome (2,6).
Transcription of the genes by RNA polymerase HI begins at early
times of infection and accelerates during the late phase (3,7,8).
The role of the VA RNAs in translation^ control was revealed
through the study of mutants which carry disruptions of the
transcriptional signals located within the genes (9). Protein
synthesis was reduced about 10-fold in cells infected with an
adenovirus mutant that cannot make VA RNA|, but proceeded
normally in cells infected with a mutant virus unable to transcribe
VA RNAU. This indicates that VA RNAr is the more important
as well as the more abundant species. In cells infected with a
doubly mutant virus, where both VA RNAs were missing, protein
synthesis was reduced 50-fold, suggesting that VA RNAn can
partially substitute for VA RNAj (10). Further studies
demonstrated that VA RNA antagonizes the activation of a
cellular protein kinase known as DAI, the double stranded RNA
(dsRNA) dependent inhibitor of protein synthesis (11,12). This
enzyme is present in many cell types at a low level, and its
synthesis is induced by interferon (13,14). When activated by
dsRNA in a process involving autophosphorylation, DAI inhibits
protein synthesis by phosphorylating the initiation factor eIF-2,
thereby trapping a second initiation factor (GEF or eIF-2B). VA
RNA, prevents the dsRNA-mediated activation of DAI,
preserving protein synthesis in the infected cell and functioning
as a viral defense mechanism to oppose the effects of interferon
(15,16).
VA RNAj binds to DAI both in vivo and in vitro and can
block the binding of the dsRNA activator (17-19). Regions of
the VA RNA molecule involved in binding DAI in vitro and
required for preventing its activation in vivo have been defined
through the use of mutants (20-22). Further progress in studying
the structure and function of the molecule depends on a convenient
method for obtaining substantial quantities of VA RNA or of its
mutant derivatives. Kinase inhibition assays and attempts at
crystallization, in particular, require large amounts of RNA. To
this end, we constructed a vector that contains a promoter for
the bacteriophage T7 RNA polymerase, allowing synthesis of
correctly initiated and terminated VA RNAt. This polymerase,
displays a high degree of promoter specificity and is easily
purified from bacteria which overexpress the polymerase gene
(23,24). Optimized transcription reactions produced copious
quantities of authentic VA RNA]. However, the product also
contained small amounts of contaminating dsRNA. Because DAI
is activated by very low concentrations of dsRNA, these
contaminants obscured the results of kinase inhibition assays. We
therefore devised a procedure to purify VA RNA[ away from
the interfering contaminants, so that it can be tested for its ability
to inhibit the activation of DAI. This procedure appears to be
broadly applicable to RNA synthesized in vitro.
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MATERIALS AND METHODS
Vector construction
Plasmid pT7VA/Ad2I, abbreviated here to pT7VA, is a
derivative of the cloning vector pUCl 19 containing the promoter
for T7 RNA polymerase (derived from pET-7; ref. 25) fused
upstream of the gene for Ad2 VA RNA, (from pMHVA; ref.
20). Run-off transcription using T7 RNA polymerase produces
exact copies of VA RNA, beginning at the major (G) start of
transcription and terminating with three uridylate residues at the
3' end (Figure 1). The plasmid contains the <f> 10 promoter of
phage T7 (nt - 3 7 to +2, Bgl II-Stu I fragment of pET-7) inserted
at the Bam HI site of the vector via a Bam/Bgl II fusion. The
StuI half-site was fused to the VA RNA, gene at nucleotide +3
after cleavage of a synthetically constructed Fsp I site introduced
at the 5' end of the Ad2 VA RNAi gene. Thus, the 5' junction
is aggGCA, where the Stu I and Fsp I half-sites are lower and
upper case, respectively, and the transcribed portion is
underlined. The 3' end of the VA RNA, gene was modified
from TTTTGG to TTTAAA using oligonucleotide-directed
mutagenesis (26), creating a Dra I restriction endonuclease site.
The downstream junction was formed by fusing a Sal I site
introduced 70 bases downstream of the VA RNA, gene to the
Sal I site in the pUCl 19 polylinker.
Transcription reactions
T7 RNA polymerase was purified as described (24). Plasmid
pT7VA DNA was banded twice in CsCl gradients, treated with
20 /xg/ml RNase A for 30 min. at 37°C in TE (10 mM
Tris-HCl, pH 8.0, 1 mM EDTA), deproteinized, then digested
with Dra I. Transcription reactions contained 37.5 /ig/ml T7 RNA
polymerase, 50 fig/ml DNA, 40 mM Tris-HCl, pH 7.8, 14 mM
MgCl2, 2mM spermidine, 5 mM dithiothreitol (DTT), 4 mM
each ribonucleoside triphosphate, and 1 unit/^il RNasin
(Promega). A trace amount (50 /tCi/ml) of a-32P-GTP was
added to follow the VA RNA through the purification scheme.
Reactions were incubated at 40°C for 90 min., terminated by
the addition of EDTA to 20 mM, then extracted once with phenol
and once with chloroform. Transcription conditions were based
on those previously reported (27) and were optimized for VA
RNA, yield by varying the temperature and time of incubation
and the concentrations of the reaction components listed above.
Substantial improvement in yield resulted from raising the
nucleotide and MgCl2 concentrations relative to standard
conditions. Other components tested, including Triton X-100,
PEG-8000, creatine phosphate plus creatinine kinase, Hepes-
KOH and BSA, did not affect the RNA yield significantly.
Purification of VA RNA,
VA RNA was recovered by ethanol precipitation, denatured in
formamide loading solution, and fractionated in an 8%
polyacrylamide/ 7M urea sequencing gel for 2.5 hours at 1.7
KV as previously described (20). The major band was excised
and VA RNA was eluted by the crush and soak technique. The
RNA was phenol extracted and precipitated with ethanol, then
resuspended in glycerol loading solution (non-denaturing) and
fractionated in an 8% polyacrylamide sequencing-type gel, cast
without urea, for 6 hours at 500 volts. The RNA was recovered
from the gel as before, dissolved in 35% ethanol/STE and loaded
onto a cellulose CF-11 column (28). VA RNA was eluted as
previously described (29) except that 22% ethanol/STE was
employed instead of 15% ethanol/STE. The fractions containing
the peak of radioactivity were pooled and the RNA was
precipitated with ethanol and dissolved in water. The nucleic acid
concentration was determined by spectrophotometry. Overall
recovery of VA RNA! after the three purification steps was
10-15% (i.e., 200-300 /xg/100 ng plasmid DNA).
Kinase assay
DAI was purified to the hydroxylapatite stage (19). Kinase assays
were performed using 1 /il of DAI fraction (134 /ig/ml), 20 mM
KC1, 5mM MgCl2, 15 mM HEPES-KOH, pH 7.4, 1 mM DTT,
10 /tM PMSF, 0.1 mM ATP, 250 /tCi/ml y-32PATP (3000
Ci/mmole, Amersham), 1 /tg/ml of aprotinin, leupeptin, and
pepstatin, in a final volume of 20 /tl. Reactions were incubated
at 30°C for 20 min and terminated by the addition of an equal
volume of 2 X SDS-gel sample buffer. Samples were heated to
100°C for 2 minutes and fractionated in 12.5% SDS-
polyacrylamide gels (30). Gels were fixed, dried and subjected
to autoradiography. When necessary, the bands containing
autophosphorylated DAI were excised and subjected to
scintillation counting.
Synthesis of synthetic dsRNA
Double stranded RNA was prepared by hybridizing
complementary strands transcribed in vitro from the plasmid
pGEM.GC, essentially as published previously (19). This plasmid
contains a 354 bp 'GC clamp' fragment (Xba I to Hind HI) from
pMHVA (20) inserted between the equivalent sites of pGEMl
(Promega). RNA generated by T7 RNA polymerase transcription
T7 promoter
I GGG TTTAAA I







Figure 1. Plasmid construction and VA RNA purification scheme. Plasmid pTTVA
contains the T7 RNA polymerase promoter (hatched) and the structural gene for
adenovirus 2 VA RNA, (open box) cloned into the polylinker of the vector pUC
119. An additional 21 nucleotide linker sequence (filled box) separates the Ad2
Bal I site (nucleotide 10810) from the Sal I site in the vector polylinker. A Dra
I site allows transcription to runoff at the 3'-end of the VA RNA structural gene.
The purification scheme developed here is outlined below.
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of pGEM.GC DNA cleaved with Nae I was annealed to RNA
generated by SP6 RNA polymerase transcription of pGEM.GC
cleaved with Sph I. After digestion with RNase A (10 /tg/ml),
dsRNA 170 bp in length was purified by electrophoresis through
an 8% polyacrylamide gel.
Ribonuclease digestion
RNA samples were digested with ribonuclease T, (RNAse T,,
Calbiochem) in TE buffer using an enzyme to substrate ratio of
1:10, or with ribonuclease IH (RNase m, purified through the
phosphocellulose stage; ref. 31) in a buffer containing 20mM
Tris-HCl, pH 7.6, lOOmM NH4CI, and lOmM Mg acetate (32)
using 1.5 units of enzyme for 5 /ig unpurified VA RNA or 10
ng reovirus dsRNA. Digestion was carried out for 30 min at
37°C. RNA was recovered by phenol extraction, chloroform
extraction, and ethanol precipitation in the presence of 20 /ig/ml
glycogen as carrier. Recovery was monitored by Cerenkov
counting.
RESULTS
Synthesis of VA RNA,
To produce large amounts of Ad2 VA RNA[ in vitro, we
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sequences with the T7 RNA polymerase promoter (Fig. 1). VA
RNA[ extracted from adenovirus-infected cells exhibits
heterogeneity at both its 5' (33-35) and 3' ends (36). The major
initiation site is at a G residue which lies three nucleotides
downstream from an A residue that serves as a minor start site.
Because the mutant virus Ad5 dl3O9 is fully viable even though
it fails to make A-start VA RNA, the predominant G-start form
is sufficient for viral growth (37). VA RNAj carries 2—6
uridylate residues at its 3' terminus, with three in the most
abundant form (36). Therefore, pT7VA was constructed such
that T7 RNA polymerase initiates at the major (G) transcriptional
start and terminates with three uridylate residues by running off
at a Dra I site. Under optimal transcription conditions, reactions
produced about 20 /tg of VA RNA] from 1 /tg of linearized
plasmid, a molar yield of 750. This represents a one thousand
fold increase over the yield obtained with RNA polymerase HI
transcription extracts from 293 cells (data not shown). The VA
RNAj was indistinguishable from that isolated from infected
cells by RNA fingerprinting (38) and nuclease sensitivity analysis
(20).
Activity of VA RNA synthesized in vitro
In initial experiments, VA RNA] was purified from the
transcription reaction by fractionation through a denaturing
polyacrylamide gel followed by a cellulose column designed to
separate single-stranded from double-stranded RNA (28). This
chromatographic procedure probably also removes impurities
derived from the gel. The resultant RNA was assayed for its
ability to inhibit activation of DAI. As shown in Fig. 2A, high
concentrations of this RNA (20 and 50 /tg/ml) blocked activation
of DAI by reovirus dsRNA (Fig. 2A, lanes 2 and 3). Lower
concentrations blocked to a lesser extent (Fig. 2A, lanes 4 and
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Figure 2. Activation and inhibition of DAI by VA RNA. Kinase assays contained
(A) VA RNA, produced in vitro by T7 RNA polymerase transcription and
purified through a denaturing gel and CF11 column, or (B) VA RNAj isolated
from Ad2-infected HeLa cells (19). The quantities of RNA added to each reaction
and the positions of VA RNA and autophosphorylated DAI are indicated. A 7-fold
longer exposure of panel B is shown below.
Figure 3. Sensitivity of VA RNA and reovirus dsRNA to RNase T, and RNase
III. (A) VA RNAI? purified as in Fig. 2 from the T7 transcription reaction, was
incubated with buffer or enzyme, deproteinized, then added to kinase assays at
the concentrations indicated. (B) Reovirus dsRNA was incubated with buffer or
enzyme, deproteinized, then added to kinase assays at the concentrations indicated.
Panels A and B are sections of the same autoradiogram. (C) Radiolabeled VA
RNA was incubated with RNase HI (lane I), RNase T, (lane 2), sample buffer
(lane 4), or not incubated (lane 3), and fractionated in a denaturing gel. The position
of radiolabeled VA RNA, is indicated.
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5). In agreement with earlier reports (11,12), similar results were
obtained with VA RNA] isolated from Ad2-infected HeLa cells
(Fig. 2B, lanes 1 and 2).
We also examined the ability of the two VA RNA preparations
to activate DAI in the absence of reovirus dsRNA. Over a wide
range of concentrations, the RNA isolated from infected cells
activated DAI only very slightly. This weak activation was visible
on an overexposed film at concentrations between 50 and 500
ng/ml VA RNA (Fig. 2B, lower panel, lanes 9 and 10). By
contrast, VA RNAi synthesized in vitro by T7 RNA polymerase
activated DAI strongly at 0.5 and 5 /tg/ml (Fig. 2A, lanes 8 and
9) although higher concentrations blocked the activation (Fig.
2A, lane 7). These results show that the VA RNA made in vitro
is functional as an inhibitor of DAI activation and suggest that
it is contaminated with an activator that is not removed by
electrophoresis through a single gel and CF11 chromatography.
To test this conclusion and determine the nature of the activator,
we incubated the VA RNA, preparation with the enzymes
RNase T] or RNase HI, specific for single-stranded and double-
stranded RNA, respectively. RNase T, cleaves RNA at unpaired
guanosine residues (38), while RNase IE digests perfectly
duplexed RNA of ^20 base pairs (and certain stem-loop
structures present in some procaryotic RNA processing sites
[39,40]). The specificity of each enzyme was authenticated by
incubation with reovirus dsRNA and VA RNA]. Radiolabeled
VA RNA, was degraded by RNase T, but not by RNase m
(Figure 3Q. Conversely, reovirus dsRNA lost its ability to
activate DAI upon incubation with RNase HI but not with RNase
T, (Figure 3B), indicating digestion of reovirus dsRNA by
RNase HI but not RNase T,. We then applied the same test to
the VA RNAj preparation used in Fig. 2A. Like reovirus RNA,
the activation of DAI by VA RNA] was sensitive to digestion
with RNase HI (Figure 3A, compare lanes 1 - 3 ) but not RNase
T, (Fig. 3A, lanes 7-9) . In fact, activation of DAI at high
concentrations of RNA was increased by RNase T] digestion,
probably because of the removal of VA RNA] that had been
masking the activity of the contaminant (Figure 3 A, lanes 4 and
7). These results indicate that the activator which is present in
the VA RNA] preparation is probably dsRNA. Judging from the
ability of the contaminant to activate DAI, we estimate that it
represents approximately 0.1 — 1% of the total mass of RNA
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Figure 4. Rationale for purification procedure. (A) Radiolabeled VA RNA, alone (lane 1), or mixed with labeled dsRNA (lane 2), was fractionated in an 8%
polyacrylamide/7M urea sequencing gel. Sections of the gel containing VA RNA (outlined) were excised. The RNAs recovered from lanes 1 and 2 were then fractionated
in lanes 3 and 4, respectively, of a non-denaturing polyacrylamide gel. The positions of the VA RNA and dsRNA are indicated. (B) Preparative denaturing sequencing
gel containing the RNA from transcription of 100 /jg of Dra I linearized pTTVA was fractionated in a denaturing gel (lane 1). The VA RNA was eluted, recovered
and further purified in a non-denaturing gel (lane 2). The positions of VA RNA and a slowly migrating contaminant (S.M.C.) are indicated. (Q VA RNA and
the S.M.C. were purified as in panel B from a functional mutant of VA RNA (sub 118— 119, Mellits, Pe'ery and Mathews, unpublished results) and were tested
for their ability to activate DAI.
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Purification of VA ,
We wanted to develop a procedure to remove the contaminant
which did not rely on digestion with the enzyme RNase m as
a purification measure. Although the contaminant copurified with
VA RNA] in a denaturing polyacrylamide gel, in view of its
structure we thought it unlikely that the two RNAs would also
co-migrate in a non-denaturing gel. To test this idea, VA RNA
was loaded onto a denaturing gel either alone or together with
partially degraded synthetic dsRNA, intended to simulate the
dsRNA contaminant (Fig. 4A, lanes 1 and 2). After
electrophoresis, the RNA migrating in the same area as VA
RNA] in each lane was excised and eluted (as outlined in Figure
4, lanes 1 and 2). The RNAs recovered were then loaded into
separate lanes of a non-denaturing polyacrylamide gel; in this
gel, the band corresponding to synthetic dsRNA migrated
considerably more slowly than VA RNAZ (Figure 4A, lanes 3
and 4).
We therefore fractionated VA RNAj synthesized from pTTVA
in a denaturing polyacrylamide gel and then in a non-denaturing
gel (Fig. 4B). When the non-denaturing gel was overexposed,
a minor band migrating more slowly than VA RNAj was
detected. This material was present in approximately the same
quantity as the proposed contaminant, and is referred to as the
slow migrating contaminant (S.M.C.). To discover whether this
material could be responsible for the activation of DAI observed
with partially purified preparations of VA RNAj, we eluted the
S.M.C. from a non-denaturing gel and performed kinase assays.
This experiment was conducted with a VA RNA] mutant, sub
118-119, which gave increased amounts of the S.M.C. band
but behaves like wild-type VA RNA in kinase inhibition assays
(Mellits, Pe'ery and Mathews, unpublished data). As shown in
Figure 4C, the S.M.C. activated DAI (Fig. 4C, lanes 3-8) ,
particularly at 5 and 0.5 /ig/ml, whereas the corresponding VA
RNA band was not able to efficiently activate the kinase (Fig.
4C, lanes 8-12). These data demonstrate that the vast majority
of the activating contaminant was removed from the mutant VA
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Figure 5. Activities of purified VA RNA, synthesized in vitro after purification.
Wild-type VA RNA, synthesized by T7 RNA polymerase was purified through
denaturing and non-denaturing gels and a CF-11 column. The resultant RNA
was tested for hs ability to activate (lanes 6-11) or prevent activation (lanes 1 -5)
of DAI in kinase assays. The lower panel is a 4-fold longer exposure of the upper
panel.
gel, and that at least some of the activator can be purified as the
S.M.C. band.
Based on these findings, we employed sequential
electrophoresis through denaturing and non-denaturing
polyacrylamide gels to purify wild-type VA RNAp As an
additional measure we subjected the eluted RNA to fractionauon
on cellulose columns. The resultant RNA was tested for its ability
to inhibit and to activate DAI (Fig. 5). A comparison between
Figures 5 and 2B indicates that the purified synthetic VA RNA|
behaves similarly to VA RNA! purified from adenovirus 2
infected cells, in both DAI activation and inhibition assays. Most
importantly, it exhibits significantly less activating activity than
synthetic VA RNAj purified only through a denaturing gel and
cellulose column (cf. Fig. 2A, lanes 7 — 11).
DISCUSSION
We have constructed a vector, pTTVA, which utilizes a phage
T7 promoter to overproduce adenovirus VA RNAj. The vector
also allows site-specific mutations to be introduced by
oligonucleotide-directed mutagenesis. Unfortunately, dsRNA is
produced during the synthesis of VA RNA by run-off
transcription with T7 RNA polymerase. This contaminant
interferes with assays of the DAI inhibitory function of the RNA
product by introducing additional quantities of an activator. The
effects can be particularly confusing because the activation of
DAI is extremely sensitive to low levels (10-50 ng/ml) of
dsRNA and high concentrations of dsRNA (1-10 /ig/ml) inhibit
activation of the enzyme (41 -43). Therefore, for use in kinase
assays, it is crucial that RNAs produced from such vectors be
purified away from dsRNA contaminants. To accomplish this,
we developed a general procedure involving electrophoresis
through sequential denaturing and non-denaturing polyacrylamide
gels followed by a simple chromatographic step (see Figure 1).
At least some of the dsRNA that is generated during the
transcription reaction co-purifies with VA RNA] in a denaturing
sequencing gel and can be visualized as a more slowly migrating
band in a subsequent non-denaturing sequencing gel. The source
of this slowly migrating contaminant is unknown. Some
preparations of T7 RNA polymerase efficiently replicate a short
RNA (X RNA) in an apparently template independent fashion
during transcription of DNA templates (44). The replication of
X RNA involves synthesis of complementary RNAs, each of
which has a hairpin structure. These strands then anneal yielding
a duplexed RNA. Although VA RNAr has a considerable degree
of secondary structure (20), it did not serve as template to
generate an 'X' type VA RNA when incubated with our T7 RNA
polymerase (data not shown). Because the yield of the slowly
migrating contaminant seemed to depend on the template used,
it is more likely to be transcribed from DNA. Low levels of
spurious DNA-dependent transcripts complementary to runoff
transcripts are produced by both SP6 and T7 RNA polymerases
(45,46). The synthesis of such transcripts is increased when short
templates with 3' overhanging ends are transcribed, but is also
observed at low levels (<1%) from DNA templates with 5'
overhanging ends or blunt ends (as used here). In our
preparations, we estimate the dsRNA contamination level to be
approximately 0.1 — 1%. It is thought that these anti-sense
transcripts are formed when some RNA polymerase molecules
do not 'run off the linearized DNA but instead swing around
and continue transcription on the opposite DNA strand (46).
Alternatively, the antisense RNA may be generated from cryptic
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promoters located on complementary strands of the plasmid
sequences.
Given the sensitivity of DAI to low concentrations of dsRNA,
contamination at a level of less than 1 % could produce enough
dsRNA to activate DAI. Removal of the contaminant by the
procedure we have developed relies largely on the differential
mobility of the VA RNA and dsRNA species in non-denaturing
and denaturing conditions (Fig. 4; ref. 47). It is likely that the
aberrant electrophoretic mobility of VA RNA] also contributes
to the separation: VA RNA, migrates with single-stranded RNA
molecules of -220 nt. in a denaturing gel and of ~ 135 nt. in
a non-denaturing gel (Pe'ery, Mellits and Mathews, in
preparation). Whatever the mechanism, it is likely that the
procedure described here can be used to purify a wide variety
of small transcripts, particularly those produced by in vitro
transcription with bacterial RNA polymerase, for use in kinase
inhibition and other assays. A case in point is the recent
demonstration (48) that purification of HTV-1 TAR RNA by the
procedure described here successfully removes dsRNA
contaminants that give spurious DAI activation. Furthermore,
this procedure may be useful for removing complementary strand
contaminants from single-stranded RNA hybridization probes.
After purification, the VA RNA, synthesized by T7 RNA
polymerase behaves like the authentic molecule purified from
infected cells in that neither of them activates DAI to a significant
extent (11,12). We estimate that, at its peak, the level of activation
observed with VA RNA is loss than 1 % of that obtained with
20 ng/ml reovirus dsRNA. Short perfect duplexes, of a length
comparable with the duplex regions in VA RNA, also activate
DAI poorly if at all (49-51; L. Manche and M.B. Mathews,
unpublished observations). These results are set against those of
Galabru et al. (18) who found that VA RNAj made in vivo
activated DAI to a significant degree (approximately 10% as well
as reovirus dsRNA; M. Katze, personal communication). It is
not clear whether the discrepancy is due to different assay
conditions, dsRNA contamination, or other factors. Our findings
are consistent with the view that adenovirus-2 VA RNA! is a
specialized effector designed to bind to the dsRNA binding site
of DAI in such a way as to prevent rather than promote activation
of the enzyme (22).
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